Immunoconjugates of soybean Bowman-Birk protease inhibitor as targeted antitumor polymeric agents

I. P. Gladysheva, N. A. Moroz, T. A. Karmakova, E. R. Nemtsova, R. I. Yakubovskaya, N. I. Larionova

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


To enhance the antitumor potential of soybean Bowman-Birk inhibitor (BBI), the conjugate of BBI with an antibody via a macromolecular carrier was prepared. Clinical dextran (D) was used as a biocompatible biodegradable carrier for co-immobilization of BBI and antibody. A model immunoglobulin isolated from sheep serum (sIgG), raised against human IgM was utilized to develop the procedure of immunoconjugate synthesis. The molar ratio of the ingredients in the conjugate was the following BBI:D:sIgG=9:1:1. Comparison of the dose response curves for the native sIgG and the BBI-D-sIgG conjugate indicated that sIgG completely retained its specific activity (>90%) after modification with dextran. The determination of the Ki values for chymotrypsin interaction with the native BBI and the BBI-D-sIgG conjugate indicated high anti-chymotrypsin activity. In the next step, the monoclonal antibody (ICO 25 MAb) against the mucin-like human epithelial membrane antigen was used for conjugation as it is the most universal vector for targeting different agents to human tumors of epithelial origin. The influence of conjugation on the specificity of the Mab reaction with its antigen was studied. The conjugated MAb reacted with tumor cells of different epithelial genesis (breast, lung, gastric, ovarian and uterus tumors), but did not react with tumor cells of non-epithelial origin. It was shown that BBI-D-ICO 25 MAb conjugate has almost the same immunohistochemical activity as non-conjugated MAb. These results demonstrated the feasibility of exploiting the activities of covalently bound BBI and ICO 25 MAb for anticarcinogenic agent targeting.

Original languageEnglish (US)
Pages (from-to)303-316
Number of pages14
JournalJournal of Drug Targeting
Issue number5
StatePublished - 2001
Externally publishedYes


  • Immunoconjugate
  • Soyabean Bowman-Birk protease inhibitor
  • Targeting
  • Tumor

ASJC Scopus subject areas

  • Pharmaceutical Science


Dive into the research topics of 'Immunoconjugates of soybean Bowman-Birk protease inhibitor as targeted antitumor polymeric agents'. Together they form a unique fingerprint.

Cite this